Provided by Tiger Fintech (Singapore) Pte. Ltd.

AC Immune SA

2.01
-0.0110-0.54%
Volume:63.95K
Turnover:128.10K
Market Cap:198.78M
PE:-3.41
High:2.05
Open:2.00
Low:1.96
Close:2.02
Loading ...

AC Immune SA Appoints Dr. Günther Staffler as Interim Executive Vice President of Development

Reuters
·
12 Jun

AC Immune SA Announces Board Changes Ahead of June 2025 AGM

TIPRANKS
·
19 May

AC Immune Sa: Martin ZÜGel Md Will Be Proposed as New Board Chair

THOMSON REUTERS
·
19 May

AC Immune Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
01 May

AC Immune Sa : H.c. Wainwright Cuts Target Price to $12 From $16

THOMSON REUTERS
·
01 May

AC Immune Q1 EPS $(0.21) Misses $(0.20) Estimate, Sales $1.10M Beat $300.67K Estimate

Benzinga
·
30 Apr

AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates

Zacks
·
30 Apr

BRIEF-AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Reuters
·
30 Apr

AC Immune: Q1 Earnings Snapshot

Associated Press Finance
·
30 Apr

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update

THOMSON REUTERS
·
30 Apr

AC Immune Sa: Cash Resources of CHF 145.7 Mln as of March 31 Provides Funding Into Q1 2027

THOMSON REUTERS
·
30 Apr

AC Immune Q1 EPS CHF -0.19

THOMSON REUTERS
·
30 Apr

AC Immune Q1 Operating Expenses CHF -20.36 Million

THOMSON REUTERS
·
30 Apr

AC Immune Q1 Pretax Profit CHF -19.029 Million

THOMSON REUTERS
·
30 Apr

AC Immune Q1 Operating Income CHF -19.37 Million

THOMSON REUTERS
·
30 Apr

Individual investors in AC Immune SA (NASDAQ:ACIU) are its biggest bettors, and their bets paid off as stock gained 11% last week

Simply Wall St.
·
26 Apr

AC Immune Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Apr

BRIEF-AC Immune SA - ACI-7104.056 Is Well Tolerated With No Safety Issues Reported To Date

Reuters
·
02 Apr

AC Immune Sa - ACI-7104.056 Is Well Tolerated With No Safety Issues Reported to Date

THOMSON REUTERS
·
02 Apr

AC Immune Reports Further Positive Interim Results From Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

THOMSON REUTERS
·
02 Apr